Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Swift Biosciences Announces $7 Million Series B Financing

Published: Friday, October 18, 2013
Last Updated: Friday, October 18, 2013
Bookmark and Share
Funds will support development of next gen sequencing and molecular diagnostic products.

Swift Biosciences, Inc. have announced the recent completion of a $7 million Series B financing led by Fletcher Spaght Ventures.  Also joining in the B round of investment was Renaissance Venture Capital Fund and the Series A investors, including the Mercury Fund, Michigan Accelerator Fund and several Michigan-based individual investors.

Swift Biosciences is a fast‐moving company focused on developing innovative, enabling

technologies for genomics and personalized medicine.  In February 2013, Swift entered the rapidly growing Next Generation Sequencing (NGS) space with its Accel-NGS™ line of sample preparation products. Swift’s myT® Primer technology provides both high sensitivity and specificity in mutation detection, making it ideal for cancer research and diagnostic applications.  myT Primer technology has been non-exclusively licensed to a global diagnostic company.

“This funding will support the expansion of our sales and marketing programs as well as accelerate new product introductions.  Our portfolio of creative, market-driven technologies continues to grow.” said David Olson, PhD, Chief Executive Officer of Swift Biosciences. 

Peter Kleinhenz, a Venture Partner with Fletcher Spaght Ventures, will be joining Swift's Board of Directors.  He commented that "We are excited about participating in the fastest growing life science market and partnering with such a talented team through our investment in Swift.  Their initial products and innovation pipeline offer compelling competitive advantages for next gen sequencing preparation, which is one of the bottlenecks in this field."  

Dr. Olson added “We are pleased to have new investors join our team and we also appreciate the continued support and enthusiasm of our existing investors.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Michigan Accelerator Fund I Invests $750,000 in Swift Biosciences
Innovative company develops enabling technologies for genomics and personalized medicine.
Friday, January 18, 2013
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!